Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
Verteporfin might be a potential cure for hair loss and could heal scars, which may lead to natural-looking results when combined with hairline lowering surgery. One person suggests waiting to see if verteporfin actually works as claimed.
A user is considering using verteporfin with microneedling, oral/topical minoxidil, and RU58841 to treat hair loss. They seek advice on dosage and application methods.
A user shared progress pictures 12 months after a hair transplant and daily use of dutasteride. The conversation discusses the quality of comparison photos and the use of hair fibers.
The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
The conversation is about the appropriate wait time to apply topical finasteride after microneedling to prevent it from going systemic. The user is combining finasteride with minoxidil and is unsure whether to wait 24 or 48 hours after microneedling before applying the treatment.
Dutasteride may not be effective for everyone due to underlying issues, suggesting scalp biopsies for further diagnosis. Users discuss using higher doses of dutasteride, topical treatments, minoxidil, and pyrilutamide for hair loss management.
The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.
The conversation is about a user's 13-month progress using oral finasteride and topical minoxidil for hair loss, showing significant improvement but considering a hair transplant for increased density. The user also takes biotin and saw palmetto, uses Hims shampoo, and plans to consult a surgeon for potential grafts.
A 22-year-old male with hair loss is considering treatments like finasteride, minoxidil, and derma rolling after being diagnosed with MPB, vitamin D deficiency, and dandruff. He seeks advice on whether these treatments can realistically improve his hair density and achieve a healthier NW2.
The conversation discusses starting finasteride for hair loss, with the original poster noting reduced scalp itching and oiliness after the first week. Users share experiences with different dosages and schedules, concerns about side effects, and the potential impact on prostate cancer detection.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started oral finasteride, which initially slowed hair loss and slightly thickened hair, but experienced increased shedding after surgery. The doctor recommended iron and vitamin D supplements, and the user is seeking additional advice.
The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.
The user shared their three-year progress using finasteride and minoxidil for hair regrowth before undergoing a hair transplant procedure. They plan to continue the medication post-procedure due to its success and did not experience significant side effects.
A 17-year-old is using topical minoxidil for hair loss and is considering other treatments like ketoconazole shampoo and saw palmetto while waiting to start finasteride at 19. Suggestions include using oral minoxidil, topical antiandrogens like RU58841, and CB-03-01, with a focus on minimizing systemic DHT impact.
Using a combination of topical finasteride, minoxidil, caffeine and dermaroller treatments to help with hair loss, while discussing the potential results and other options.
Consider increasing dutasteride dosage to 2.5mg daily and continue using oral minoxidil. Check DHT levels, thyroid, vitamin D, and consider additional treatments like microneedling, RU58841, and improving diet and lifestyle.
The user is starting a new hair loss treatment routine with Minoxidil, Redensyl, Ketoconazole shampoo, and microneedling. They are avoiding finasteride due to potential side effects and are considering future treatments like pyrilutamide.
The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.
The conversation discusses a year-long hair loss treatment from February 28, 2022, to February 28, 2023, which included daily oral finasteride (1mg), biotin supplements, and the Curly Girl Method. Progress pictures were shared to show the results.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
A user shared their positive experience with a 2987 graft hair transplant focused on the hairline, supplemented by finasteride and minoxidil for the mid scalp and crown. They expressed satisfaction with the results and the supportive care received during and after the procedure.
PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.